• PCN20 COSTO EFECTIVIDAD DE LA UTILIZACIÓN DE INHIBIDORES DE PUNTOS DE CONTROL INMUNITARIO (ANTI-PD1/ANTI-CTLA4) Y TERAPIAS DIRIGIDAS (BRAFI/MEKI) EN EL TRATAMIENTO DEL MELANOMA AVANZADO.

    Oct 1, 2019, 00:00

  • PDB15 SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITOR IN TYPE 2 DIABETES: PRESCRIPTION PATTERNS AND TREATMENT OUTCOMES IN ARGENTINA

    Oct 1, 2019, 00:00

  • PBI4 COMPORTAMIENTO DE USO DE TERAPIA BIOLÓGICA Y COSTOS ASOCIADOS DE UN PROGRAMA DE ATENCIÓN EN PACIENTES CON DIAGNASTICO DE ARTRITIS REUMATOIDE EN COLOMBIA

    Oct 1, 2019, 00:00

  • PAM3 COST MINIMIZATION BETWEEN READY TO USE OLIVE OIL-BASED PARENTERAL NUTRITION AND SUBROGATE COMPOUNDED PARENTERAL NUTRITION, ANALYSIS FROM A HIGH SPECIALITY REGIONAL MEXICAN HOSPITAL.

    Oct 1, 2019, 00:00

  • PCN15 IMPACTO ECONOMICO DE LAS COMPLICACIONES OSEAS EN PACIENTES CON CANCER DE MAMA METASTASICO (CAMM) EN MEXICO.

    Oct 1, 2019, 00:00

  • PNS16 ANALYSIS OF THE DEMAND AND CONCESSIONS OF THE CONTINUED CASH BENEFIT FOR PERSONS WITH DISABILITIES UNDER 16 YEARS

    Oct 1, 2019, 00:00

  • PIN6 O IMPACTO ECONOMICO NA AVALIACAO DO INFECTOLOGISTA NO PROGRAMA DE GESTAO CLINICA DO USO DE ANTIMICROBIANOS EM HOSPITAL PRIVADO DE FORTALEZA- CE, BRASIL

    Oct 1, 2019, 00:00

  • PIN12 COST-EFFECTIVENESS OF INTERFERON-GAMMA RELEASE ASSAY COMPARED TO TUBERCULIN SKIN TEST FOR DETECTION OF LATENT TUBERCULOSIS IN RHEUMATOID ARTHRITIS PATIENTS USING IMMUNOBIOLOGICAL TREATMENTS

    Oct 1, 2019, 00:00

  • PDG10 DRUGS WITH DISCONTINUED PRODUCTION: A DESCRIPTIVE ANALYSIS OF THE BRAZILIAN SCENARIUM

    Oct 1, 2019, 00:00

  • PNS38 INVESTIGATING QUALITY AND PERFORMANCE INDICATORS RELATED TO OUTPATIENT CARE USING THE DELPHI METHOD

    Oct 1, 2019, 00:00

  • CL2 EFFECTIVENESS OF TREATMENT WITH DIRECT-ACTING ANTIVIRALS IN THE COLOMBIAN POPULATION WITH CHRONIC HEPATITIS C

    Oct 1, 2019, 00:00

  • PND15 CHARACTERIZATION OF THE ARGENTINE POPULATION WITH AT LEAST 4 MONTHLY MIGRAINE DAYS: RESULTS FROM MIGRAINE VOICE SURVEY

    Oct 1, 2019, 00:00

  • PIN26 PRINCIPALES ESQUEMAS ANTIRRETROVIRALES USADOS EN LAS PERSONAS QUE VIVEN CON EL VIH EN COLOMBIA. 2018

    Oct 1, 2019, 00:00

  • PIH16 PATRONES DE USO DE ANTICONCEPTIVOS HORMONALES EN UNA POBLACIÓN DE COLOMBIA.

    Oct 1, 2019, 00:00

  • PDB14 LOVASTATIN, ATORVASTATIN AND ROSUVASTATIN CONSUMPTION IN COLOMBIA FROM 2010 TO 2017

    Oct 1, 2019, 00:00

  • PCN9 ANÁLISIS DE IMPACTO PRESUPUESTAL DE LA DETECCIÓN TEMPRANA DEL CÁNCER DE CUELLO UTERINO EN MUJERES DE 30 A 65 AÑOS MEDIANTE TAMIZACIÓN CON TEST DE VPH Y GENOTIPIFICACIÓN FRENTE CITOLOGÍA CONVENCIONAL, EN COLOMBIA

    Oct 1, 2019, 00:00

  • PNS45 APPLYING A RAPID REVIEW METHODOLOGY TO INFORM THE UPDATE OF ARGENTINA'S HEALTH BENEFIT PACKAGE

    Oct 1, 2019, 00:00

  • PCN35 BURDEN OF DISEASE FOR ADVANCED BREAST CANCER IN BRAZIL

    Oct 1, 2019, 00:00

  • TP1 TRATAMIENTO DEL CANCER DE MAMA ESTADIO IV, ANÃLISIS DE LOS DATOS REPORTADOS A LA CUENTA DE ALTO COSTO. COLOMBIA 2017

    Oct 1, 2019, 00:00

  • RE3 RELAPSING-REMITTING MULTIPLE SCLEROSIS: COSTS BENEFITS OF EXPANDING COVERAGE FROM A PUBLIC PAYER PERSPECTIVE

    Oct 1, 2019, 00:00

  • PRO11 ANÁLISIS DE SERIE DE CASOS DE PACIENTES CON DIAGNÓSTICO DE HEMOFILIA A CON INHIBIDORES EN HOSPITALES DE ALTA COMPLEJIDAD EN ECUADOR

    Oct 1, 2019, 00:00

  • HT3 BASE DE COSTOS UNITARIOS EN SALUD EN ARGENTINA: UNA FUENTE DE INFORMACIÓN CONTINUAMENTE ACTUALIZADA PARA EVALUACIONES ECONOMICAS Y ANALISIS DE IMPACTO PRESUPUESTARIO EN UN SISTEMA DE SALUD FRAGMENTADO

    Oct 1, 2019, 00:00

  • PMH7 COST-EFFECTIVENESS AND INCORPORATION PRICE OF ARIPIPRAZOLE FOR SCHIZOPHRENIA IN BRAZIL: A SUBSTITUTE TECHNOLOGY APPROACH

    Oct 1, 2019, 00:00

  • PNS25 COMPARING THE REMUNERATION OF HOSPITAL NURSES IN COUNTRIES WITH BISMARCK AND BEVERIDGE HEALTH CARE SYSTEMS

    Oct 1, 2019, 00:00

  • PCN23 IMPACTO ECONOMICO DE CANCER DE CUELLO UTERINO Y SU TENDENCIA AL 2030 EN EL SISTEMA DE SALUD PUBLICO DEL PERU

    Oct 1, 2019, 00:00

  • PMH11 BURDEN OF MENTAL ILLNESS IN THE PRESENCE OF CHRONIC DISEASES IN THE BRAZILIAN PRIVATE HEALTH

    Oct 1, 2019, 00:00

  • PAM5 AVALIAÇÃO DO USO DA OZONIOTERAPIA EM PACIENTES COM DOR LOMBAR: UM ESTUDO DE METANALISE

    Oct 1, 2019, 00:00

  • PNS37 REVIEW OF QUALITY AND PERFORMANCE INDICATORS RELATED TO INPATIENT CARE IN SELF-FUNDED HEALTH PLANS

    Oct 1, 2019, 00:00

  • PMU9 ESTABLISHING CHILE RICARTE SOTO LAW REIMBURSEMENT CAP IN THE FACE OF GENERIC COMPETITION

    Oct 1, 2019, 00:00

  • PND16 PREFERENCES OF PATIENTS FOR FEATURES OF INJECTABLE, ORAL, AND INFUSED DISEASE-MODIFYING TREATMENTS FOR RELAPSE-REMITTING MULTIPLE SCLEROSIS

    Oct 1, 2019, 00:00

  • PCN6 COSTO-EFECTIVIDAD DEL ESQUEMA DABRAFENIB EN COMBINACIÓN CON TRAMETINIB EN COMPARACIÓN CON OTRAS TERAPIAS DIRIGIDAS, INMUNOTERAPIA Y DACARBAZINA PARA EL TRATAMIENTO DE MELANOMA IRRESECABLE O METASTÁSICO CON MUTACIÓN BRAFV600 EN COLOMBIA ...

    Oct 1, 2019, 00:00

  • PCN2 EFECTIVIDAD DE LA MAMOGRAFIA EN MUJERES MENORES DE 40 AÑOS: REVISION SISTEMATICA.

    Oct 1, 2019, 00:00

  • PNS10 THE PENALTY OF MATERNITY FOR LABOR MARKET IN BRAZIL

    Oct 1, 2019, 00:00

  • PMD9 COST-EFFECTIVENESS ANALYSIS OF THREE-DIMENSIONAL TRANSESOPHAGEAL ECHOCARDIOGRAPHY VERSUS TWO-DIMENSIONAL TRANSESOPHAGEAL ECHOCARDIOGRAM FOR THE EVALUATION OF PATIENTS WITH MITRAL REGURGITATION WITH INDICATION OF SURGICAL TREATMENT

    Oct 1, 2019, 00:00

  • PSY5 QUALITY OF LIFE OF INDIVIDUALS WITH PSORIASIS IN LATIN AMERICA

    Oct 1, 2019, 00:00

  • PAM4 ANALISE DOS CUSTOS DE TERAPIAS NUTRICIONAIS APOS ACOES DE AUDITORIA: UMA ANALISE DE DADOS DO MUNDO REAL

    Oct 1, 2019, 00:00

  • PND14 OUT-OF-POCKET EXPENDITURE IN MIGRAINE PATIENTS WITH AND WITHOUT COMORBIDITIES IN CHILE: A HEALTHCARE SYSTEM PERSPECTIVE

    Oct 1, 2019, 00:00

  • PCN8 FINANCIAMIENTO DE MEDICAMENTOS ONCOLOGICOS MEDIANTE EL FONDO INTANGIBLE SOLIDARIO DE SALUD DEL PERU

    Oct 1, 2019, 00:00

  • PGI5 BURDEN OF LIVER DISEASE, COLOMBIA 2009-2016

    Oct 1, 2019, 00:00

  • PNS58 RESULTADOS DE UM PROGRAMA DE ATENDIMENTO EM SAÚDE EM ÁREAS REMOTAS DA AMAZÔNIA OCIDENTAL BRASILEIRA

    Oct 1, 2019, 00:00

  • PCN33 PERTUZUMAB+TRASTUZUMAB TREATMENT ON HER2+ EARLY BREAST CANCER: LONG-TERM REDUCTION OF METASTASIC BREAST CANCER INCIDENCE IN ARGENTINA.

    Oct 1, 2019, 00:00

  • PDG7 EVALUACION ECONOMICA DE DEXAMETASONA IMPLANTE PARA EL TRATAMIENTO DE PACIENTES CON EDEMA MACULAR DIABETICO CON FALLA A LA TERAPIA ANTI-VEGF (RANIBIZUMAB O AFLIBERCEPT)

    Oct 1, 2019, 00:00

  • PDB10 COST-EFFECTIVENESS ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IN TYPE 1 DIABETES MELLITUS COMPARED WITH MULTIPLE DAILY INJECTIONS IN THE RUSSIAN FEDERATION

    Oct 1, 2019, 00:00

  • PCV11 BURDEN OF STERNAL WOUND INFECTIONS FOLLOWING CORONARY ARTERY BYPASS GRAFT PROCEDURE IN SELECT COUNTRIES

    Oct 1, 2019, 00:00

  • PNS15 DOES FOOD INSECURITY AFFECT PERFORMANCE AT SCHOOL? EVIDENCE FROM BRAZIL

    Oct 1, 2019, 00:00

  • PMU3 COSTOS DIRECTOS DE LA ATENCIÓN EN PACIENTES SUSCEPTIBLES DE CUIDADOS PALIATIVOS, EL CASO DE UNA ASEGURADORA EN SALUD EN COLOMBIA

    Oct 1, 2019, 00:00

  • HI4 ADHERENCE TO TREATMENT IS ASSOCIATED WITH GOOD CLINICAL RESULTS IN PATIENTS TREATED WITH BIOLOGICAL THERAPY IN A CENTER OF EXCELLENCE IN RHEUMATOID ARTHRITIS

    Oct 1, 2019, 00:00

  • PUK1 COST CONSEQUENCE ANALYSIS OF A REMOTE MONITORING PROGRAM TO IMPROVE CLINICAL PRACTICE OF AUTOMATED PERITONEAL DYALISIS IN COLOMBIA

    Oct 1, 2019, 00:00

  • PIN20 OVERVIEW OF MORTALITY DUE TO ANTIMICROBIAL RESISTANT INFECTIONS

    Oct 1, 2019, 00:00

  • PCN27 BUDGET IMPACT ANALYSIS OF MIDOSTAURIN IN PATIENTS WITH NEWLY DIAGNOSED FLT3 MUTATION-POSITIVE ACUTE MYELOID LEUKEMIA

    Oct 1, 2019, 00:00

  • MT4 ANALISIS DE IMPACTO PRESUPUESTARIO SOBRE LA INCORPORACION DEL COCIENTE SFLT-1/PLGF PARA PREDECIR EL RIESGO DE PREECLAMPSIA EN LA COBERTURA DE LAS OBRAS SOCIALES NACIONALES DE ARGENTINA

    Oct 1, 2019, 00:00

  • PCN31 BURDEN OF DISEASE FOR ADVANCED BREAST CANCER IN MEXICO

    Oct 1, 2019, 00:00

  • PCN13 EVENTOS ADVERSOS ASOCIADOS A LOS TRATAMIENTOS DEL CARCINOMA UROTERIAL DE VEJIGA Y EL CARCINOMA DE CELULAS RENALES: ESTIMACION DE COSTOS DIRECTOS PARA ARGENTINA

    Oct 1, 2019, 00:00

  • PIH3 BUDGET IMPACT ANALYSIS OF MEDICINES FOR CONTROLLED OVARIAN STIMULATION IN THE TREATMENT OF INFERTILITY IN PATIENTS WITH AN SUBOPTIMAL OVARIAN RESPONSE IN THE RUSSIAN FEDERATION

    Oct 1, 2019, 00:00

  • PDB9 ESTUDIO DE COSTOS DE LA HIPOGLICEMIA EN PACIENTES CON DIABETES MELLITUS TIPO 2 DESDE LA PERSPECTIVA DE SALUD PUBLICA DE CHILE

    Oct 1, 2019, 00:00

  • CN1 CALIDAD DE VIDA RELACIONADA A LA SALUD Y COSTOS DEL SISTEMA DE SALUD, POR PÉRDIDA DE PRODUCTIVIDAD Y OTROS DE PACIENTES CON DIAGNOSTICO DE CÁNCER DE MAMA EN AMÉRICA LATINA Y EL CARIBE: REVISIÓN SISTEMÁTICA Y META-ANALISIS

    Oct 1, 2019, 00:00

  • PCN24 COST-EFFECTIVENESS OF NIVOLUMAB COMBINED WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA FOR PATIENTS WITH BRAF+ MUTATION FROM A BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE

    Oct 1, 2019, 00:00

  • PDG15 SOLICITAÇÃO DE MEDICAMENTOS DO COMPONENTE ESPECIALIZADO NO ESTADO DE MINAS GERAIS: ESTRATÉGIA PARA REDUÇÃO DO TEMPO DE TRAMITAÇÃO E OTIMIZAÇÃO DESSE PROCESSO

    Oct 1, 2019, 00:00

  • PDG1 POLIMIXINA B: EXISTEM FATORES DE RISCO ASSOCIADOS À NEFROTOXICIDADE EM PACIENTES QUE UTILIZARAM ESTE MEDICAMENTO?

    Oct 1, 2019, 00:00

  • PSY7 VENOUS THROMBOEMBOLISM DISEASE: DIRECT COSTS ASSOCIATED WITH ITS TREATMENT IN ARGENTINA

    Oct 1, 2019, 00:00

  • PRO9 PUBLIC PURCHASES OF ECULIZUMABE BY THE BRAZILIAN MINISTRY OF HEALTH: A PROFILE OF VOLUMES AND EXPENSES FROM 2007 TO 2018

    Oct 1, 2019, 00:00

  • PCV10 EPIDEMIOLOGICAL STUDY DESIGN TO UNDERSTAND CARDIOVASCULAR RISK FACTORS AND TREATMENT IN GENERAL PRACTICE PATIENTS IN LATIN AMERICA

    Oct 1, 2019, 00:00

  • PCN30 REAL-WORLD DATA FOR COSTS RELATED TO CANCER MANAGEMENT IN BRAZIL: AN OVERVIEW OF THE LITERATURE

    Oct 1, 2019, 00:00

  • PMH4 STROKE IN BRAZIL: COST OF ILLNESS ON THE LENGTH OF SATY IN HOSPITAL

    Oct 1, 2019, 00:00

  • PCV8 COST-EFFECTIVENESS ANALYSIS OF A RHEOLYTIC THROMBECTOMY SYSTEM FOR THE TREATMENT OF DEEP VEIN THROMBOSIS IN MEXICO

    Oct 1, 2019, 00:00

  • PIN1 COST-EFFECTIVENESS ANALYSIS OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE FOR HIGH RISK PATIENTS IN THE PERSPECTIVE OF BRAZILIAN NIP

    Oct 1, 2019, 00:00

  • PIN23 EVALUACIÓN DE LAS PROPIEDADES PSICOMÉTRICAS DEL EQ-5D-5L EN PACIENTES CON VIH/SIDA EN COLOMBIA

    Oct 1, 2019, 00:00

  • PIH18 EVALUATION OF INFORMATION SHARING IN CONNECTION WITH SCHOOL HEALTH ATTENDANCE AND ITS EFFECTS ON THE ATTENDANCE OF HEALTH SERVICE

    Oct 1, 2019, 00:00

  • CE4 TRATAMIENTOS PARA LOS PACIENTES CON ESCLEROSIS MULTIPLE REMITENTE RECURRENTE CON ALTA ACTIVIDAD DE LA ENFERMEDAD: ANALISIS COSTO EFECTIVIDAD EN MEXICO

    Oct 1, 2019, 00:00

  • PNS57 REAL WORLD EVIDENCE LANDSCAPE IN LATIN AMERICA HEALTH CARE DECISION MAKING: EXPLORING UNDERSTANDING, ACCEPTABILITY AND USE

    Oct 1, 2019, 00:00

  • PND9 BUDGET IMPACT ANALYSIS OF CLADRIBINE COMPARED TO THE CURRENT COVERAGE SCHEME IN CHILE TO TREAT PATIENTS WITH HIGHLY ACTIVE RELAPSING REMITTING MULTIPLE SCLEROSIS

    Oct 1, 2019, 00:00

  • PND18 THE RESTORE REGISTRY: A RESOURCE FOR MEASURING AND IMPROVING SPINAL MUSCULAR ATROPHY OUTCOMES

    Oct 1, 2019, 00:00

  • PCN48 HEALTH TECHNOLOGY ASSESSMENT DECISIONS IN ONCOLOGY-RELATED TECHNOLOGIES IN BRAZIL: AN ASSESSMENT CONITEC'S RECOMMENDATIONS FROM 2012-2018

    Oct 1, 2019, 00:00

  • PMU15 A MOBILE PHONE APP HEALTH CARE PROGRAM IN BRAZIL: SELF-REPORTS TO ASSESS DISEASE PREVALENCE

    Oct 1, 2019, 00:00

  • PUK4 FACTORES ASOCIADOS DE LA PROGRESION DE LA ENFERMEDAD RENAL CRONICA EN UN PROGRAMA DE INTERVENCION DEL RIESGO CARDIOVASCULAR DEL CARIBE COLOMBIANO

    Oct 1, 2019, 00:00

  • PCN26 IMPACTO DE LAS RECAÍDAS EN LOS PACIENTES COLOMBIANOS CON LINFOMA FOLICULAR

    Oct 1, 2019, 00:00

  • PRO10 EXPERIENCIA INTERNACIONAL EN EL USO DE ANÁLISIS DE DECISIÓN MULTICRITERIO (MCDA) PARA EVALUAR MEDICAMENTOS HUÉRFANOS: SCOPING REVIEW

    Oct 1, 2019, 00:00

  • HI2 EVALUATION OF THE MEDICAL PROCEDURES ON AN ADMINISTRATIVE DATABASE TO IDENTIFY PATIENTS WITH SUSPECTED PRE-ECLAMPSIA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

    Oct 1, 2019, 00:00

  • PDB2 SELF-MONITORING OF BLOOD GLUCOSE (SMBG) LEVELS IN SELECTED LATIN AMERICAN COUNTRIES — HOW DOES IT MEASURE UP TO MAJOR GLUCOSE MONITORING GUIDELINES?

    Oct 1, 2019, 00:00

  • PIN18 BURDEN OF ILLNESS OF HERPES ZOSTER IN COLOMBIA: AN OBSERVATIONAL STUDY

    Oct 1, 2019, 00:00

  • PMU2 COSTOS DIRECTOS MÉDICOS EN COLOMBIA DESCRITOS EN EL ESTUDIO COMPASS: EVENTOS CARDIACOS AGUDOS MAYORES (MACE) Y EVENTOS ISQUEMICOS SEVEROS EN EXTREMIDADES (MALE)

    Oct 1, 2019, 00:00

  • TP2 COSTS AND PRESCRIPTION PATTERN OF PATIENTS WITH PSORIATIC ARTHRITIS AND ITS ASSOCIATED COSTS

    Oct 1, 2019, 00:00

  • PCV14 IMPACTO DE LA INTERVENCION FARMACEUTICA (IF) EN LA NO ADHERENCIA A TRATAMIENTOS POR OMISION DE RETIRO DE MEDICAMENTOS FINANCIADOS

    Oct 1, 2019, 00:00

  • PDB6 COSTO DE OBESIDAD Y SU TENDENCIA AL 2030 EN EL SISTEMA DE SALUD PUBLICO DEL PERU

    Oct 1, 2019, 00:00

  • PDG12 EXPERIENCIA INTERNACIONAL EN VALOR TERAPÉUTICO Y PRECIO BASADO EN VALOR. REVISIÓN RÁPIDA DE LA LITERATURA

    Oct 1, 2019, 00:00

  • PCN19 ANÃLISE DO CUSTO-EFETIVIDADE DA RADIOTERAPIA COM INTENSIDADE MODULADA NO TRATAMENTO DO CÃNCER DE PRÃSTATA LOCALIZADO

    Oct 1, 2019, 00:00

  • PIH11 ESTIMACION DE LA VARIACION DE COSTOS PRIVADOS E INSTITUCIONALES DE TRATAMIENTO DE LA DISMENORREA PRIMARIA EN MUJERES MEXICANAS.

    Oct 1, 2019, 00:00

  • PIN8 ANALISE ECONOMICA DE CUSTOS DE TRATAMENTO DE INFECCOES POR MICROORGANISMOS GRAM-POSITIVOS RESISTENTES: STAPHYLOCOCCUS AUREUS RESISTENTE A METICILINA (MRSA) E ENTEROCOCCUS SPP RESISTENTES A VANCOMICINA (VRE)

    Oct 1, 2019, 00:00

  • PNS47 ANÁLISIS PARA LA IMPLEMENTACIÓN DE NUEVOS MODELOS DE ACCESO PARA EL SISTEMA NACIONAL DE SALUD DEL ECUADOR

    Oct 1, 2019, 00:00

  • HT1 TRANSFERIBILIDAD DE LAS EVALUACIONES ECONOMICAS PARA LA TOMA DE DECISIONES: UNA REVISION DE REVISIONES SISTEMATICAS

    Oct 1, 2019, 00:00

  • PMS4 MEDICATION PATTERNS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS - CHARACTERISTICS AND COSTS OF THERAPY

    Oct 1, 2019, 00:00

  • PMU14 USO DEL EQ-5D EN MEXICO

    Oct 1, 2019, 00:00

  • PSY2 SECUKINUMAB VS ADALIMUMAB E INFLIXIMAB PARA EL TRATAMIENTO DE ESPONDILITIS ANQUILOSANTE: UN ANÁLISIS DE COSTO POR RESPONDEDOR A LA SEMANA 24 DESDE UNA PERSPECTIVA PERUANA

    Oct 1, 2019, 00:00

  • PMD5 ANALISIS DEL IMPACTO SANITARIO Y PRESUPUESTARIO POR LA INCORPORACION DEL TEST DE HPV CON GENOTIPIFICACION PARA EL TAMIZAJE PRIMARIO DE CANCER CERVICAL EN UNA POBLACION CERRADA DE UN HOSPITAL UNIVERSITARIO DE LA CIUDAD DE BUENOS AIRES

    Oct 1, 2019, 00:00

  • PIN2 SISTEMA ELETRONICO INTEGRADO NO GERENCIAMENTO DO PROGRAMA STEWARDSHIP NUMA OPERADORA DE PLANOS DE SAUDE

    Oct 1, 2019, 00:00

  • PIN11 COST-EFFECTIVENESS OF INTERFERON-GAMMA RELEASE ASSAY COMPARED TO TUBERCULIN SKIN TEST FOR DETECTION OF LATENT TUBERCULOSIS IN PATIENTS WITH RENAL FAILURE UNDERGOING HEMODIALYSIS

    Oct 1, 2019, 00:00

  • PCN59 SUBJECT TRAINING IS NEEDED FOR KEY TERMINOLOGY IN ONCOLOGY CLINICAL TRIALS

    Oct 1, 2019, 00:00

  • PNS1 ¿EXISTE SUFICIENTE EVIDENCIA PARA USAR SUPERVIVENCIA GLOBAL Y CALIDAD DE VIDA COMO DESENLACES CRÍTICOS EN LA TOMA DE DECISIONES EN SALUD?

    Oct 1, 2019, 00:00

  • PAM1 RESULTADOS DE LA IMPLEMENTACION DEL MODELO DE SOPORTE NUTRICIONAL EN LOS NIVELES HOSPITALARIO Y DOMICILIARIO

    Oct 1, 2019, 00:00

  • PSY8 CURRENT PRACTICE AND RESOURCE USE ASSOCIATED WITH TREATMENT OF VENOUS THROMBOEMBOLISM DISEASE IN SOCIAL SECURITY SECTOR OF ARGENTINA

    Oct 1, 2019, 00:00

  • PCN38 SYSTEMATIC REVIEW OF RISK SHARING AGREEMENT IN ONCOLOGY: ADVANCES OR MORE OF THE SAME?

    Oct 1, 2019, 00:00

  • PCN45 COMPARATIVE ANALYSIS OF BRA CMED, GER G-BA AND FRA HAS ASSESSMENT SCORES FOR ONCOLOGY THERAPIES

    Oct 1, 2019, 00:00

  • PBI6 EVALUATION OF BIOLOGIC THERAPIES FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN COLOMBIA: A COST PER RESPONDER ANALYSIS (CPR)

    Oct 1, 2019, 00:00

  • PMD12 HOW MUCH CAN COLOMBIAN HOSPITALS EARN FOR EACH THERAPEUTIC PLASMA EXCHANGE (TPE) PROCEDURE? A MULTI-CENTER, COST COMPARISON STUDY BETWEEN CENTRIFUGAL AND MEMBRANE SYSTEMS

    Oct 1, 2019, 00:00

  • PCN47 PEG-ASPARAGINASE E L-ASPARAGINASE NATIVA DE ESCHERICHIA COLI NO TRATAMENTO FARMACOLOGICO DA LEUCEMIA LINFOBLASTICA AGUDA EM CRIANCAS E ADOLESCENTES: UMA REVISAO SISTEMATICA

    Oct 1, 2019, 00:00

  • PIN22 LOS COSTOS DE LA NEUMONIA ADQUIRIDA EN LA COMUNIDAD Y LA LACTANCIA MATERNA COMO FACTOR DE PROTECCION EN MENORES DE 5 ANHOS EN HOSPITAL PUBLICO DEL PERU

    Oct 1, 2019, 00:00

  • PNS41 VALUE BASED HEALTH CARE (CUIDADO BASADO EM VALOR) EN AMERICA LATINA: RESULTADOS PRELIMINARES DE UNA INVESTIGACION CON 40 HOSPITALES DE CINCO PAISES LATINOAMERICANOS

    Oct 1, 2019, 00:00

  • PDB11 BUDGET IMPACT ANALYSIS OF SWITCHING FROM ALOGLIPTIN TO VILDAGLIPTIN IN THE TREATMENT OF TYPE 2 DIABETES

    Oct 1, 2019, 00:00

  • PSU3 DETERMINACION DE CAMBIOS QUERATOMETRICOS POST QUIRURGICOS EN PACIENTES SOMETIDOS A PRK O LASIK MEDIANTE LASER EXCIMER VISX STAR S4IR

    Oct 1, 2019, 00:00

  • PSU6 ESTUDIO DE COSTO EFECTIVIDAD ENTRE HEPARINA NO FRACCIONADA Y HEPARINAS DE BAJO PESO MOLECULAR EN PACIENTES SOMETIDOS A ARTROPLASTIA TOTAL DE CADERA ELECTIVA

    Oct 1, 2019, 00:00

  • PSY10 COST-EFFECTIVENESS ANALYSIS OF DRUG CHALLENGE TEST COMPARED TO SPECIFIC IGE DOSAGE FOR THE DIAGNOSIS OF PATIENTS WITH SUSPECT OF PENICILLIN ALLERGY

    Oct 1, 2019, 00:00

  • PIN9 PUBLIC HEALTH AND ECONOMIC IMPACT OF A GENDER-NEUTRAL QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINATION PROGRAM IN COLOMBIA

    Oct 1, 2019, 00:00

  • PGI6 CARGA DE ENFERMEDAD DIARREICA AGUDA ASOCIADA A MALA CALIDAD DEL AGUA, FALTA DE SANEAMIENTO E HIGIENE DE MANOS EN COLOMBIA, 2016

    Oct 1, 2019, 00:00

  • PIN10 PUBLIC HEALTH AND ECONOMIC IMPACT OF A HUMAN PAPILLOMAVIRUS VACCINATION PROGRAM FOR FEMALES AGED 9 YEARS IN EL SALVADOR

    Oct 1, 2019, 00:00

  • CV2 MODELO PREDICTIVO DEL RIESGO DE MUERTE EN PACIENTES DIABETICOS APLICADO EN UNA COMPAÑIA DE ASEGURAMIENTO EN SALUD DE COLOMBIA

    Oct 1, 2019, 00:00

  • PMS5 USE OF AN ALGORITHM WITHIN A MULTIDISCIPLINARY CONSULTATION FOR THE MANAGEMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS CANDIDATES FOR BIOLOGICAL THERAPY - A STRATEGY FOR OPTIMIZING COSTS

    Oct 1, 2019, 00:00

  • PNS53 DESCRIPTION OF CLINICAL CHARACTERISTICS AND SELF REPORTED WILLINGNESS TO PAY FOR NEW TREATMENTS IN COLOMBIAN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS

    Oct 1, 2019, 00:00

  • PMU13 A MULTI-CRITERIA APPROACH TO THE STUDY OF CHRONIC NON-COMMUNICABLE DISEASES IN BRAZIL

    Oct 1, 2019, 00:00

  • PCN40 COSTS OF COMPREHENSIVE CARE OF HEPATOCELLULAR CARCINOMA IN A MODEL PUBLIC PROVIDER IN CHILE: IS IT POSSIBLE TO PROMOTE FINANCIAL COVERAGE?

    Oct 1, 2019, 00:00

  • PMS18 COST-ANALYSIS OF TREATMENT FOR MODERATE AND SEVERE RHEUMATOID ARTHRITIS IN A SPECIALIZED RHEUMATOLOGY CENTER

    Oct 1, 2019, 00:00

  • PCN46 ASSESSING THE QUALITY OF THE EVIDENCE OF NIVOLUMAB ACCORDING TO THE HTA REQUIREMENT IN ARGENTINA

    Oct 1, 2019, 00:00

  • CV1 CARDIOVASCULAR RISK IN DIABETES PATIENTS MONITORED BY A MOBILE PHONE APP HEALTH CARE PROGRAM IN BRAZIL

    Oct 1, 2019, 00:00

  • PMS12 BENEFICIOS CLINICOS Y ECONOMICOS EN LA IMPLEMENTACION DE UNIDADES DE COORDINACION DE FRACTURAS (FLS) EN MEXICO

    Oct 1, 2019, 00:00

  • PCN37 FDA NEW DRUGS APPROVAL FOR BREAST, COLORECTAL, PROSTATE AND LUNG CANCER AND HORIZON SCANNING OPPORTUNITY

    Oct 1, 2019, 00:00

  • PBI9 MEDICATION USE AND REASONS FOR SWITCHING BIOLOGIC THERAPY IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: FINDINGS FROM A GLOBAL SURVEY

    Oct 1, 2019, 00:00

  • PMS17 PATIENT PREFERENCES FOR BIOLOGIC AND BIOSIMILAR OSTEOPOROSIS TREATMENTS IN COLOMBIA: A DISCRETE-CHOICE EXPERIMENT

    Oct 1, 2019, 00:00

  • PIH14 BURDEN OF PNEUMOCOCCAL DISEASE HOSPITALIZATIONS IN OLDER ADULTS 60Y+ IN FIVE CAPITALS IN BRAZIL

    Oct 1, 2019, 00:00

  • PDB3 PHARMACIST LED INTERVENTION ON HEALTH-RELATED QUALITY OF LIFE OF DIABETIC PATIENTS AND ITS RELATIONSHIP WITH PATIENT DEMOGRAPHICS ON EQ-5D DOMAINS AND VAS SCORE

    Oct 1, 2019, 00:00

  • MT1 ANÁLISIS COSTO-EFECTIVIDAD DE UN SISTEMA DE TROMBECTOMÍA REOLÍTICA PARA EL TRATAMIENTO DE LA ISQUEMIA AGUDA DE MIEMBROS INFERIORES EN ADULTOS MEXICANOS

    Oct 1, 2019, 00:00

  • PNS7 THE PRICE OF SUBSTITUTE TECHNOLOGIES

    Oct 1, 2019, 00:00

  • PNS19 AN ANALYSIS OF CONTINUED CASH BENEFIT: PERSONS WITH DISABILITIES OVER 16 YEARS OLD

    Oct 1, 2019, 00:00

  • PRO13 IMPACT OF CAREGIVER EXPERIENCE AND HRQOL IN LATER-ONSET SPINAL MUSCULAR ATROPHY (SMA): RESULTS FROM THE PHASE 3 CHERISH TRIAL

    Oct 1, 2019, 00:00

  • PND2 TREATMENTS FOR HIGHLY ACTIVE RELAPSING REMITTING MULTIPLE SCLEROSIS: COST-EFFECTIVENESS ANALYSIS IN COLOMBIA

    Oct 1, 2019, 00:00

  • PCN12 COST-EFFECTIVENESS OF PEMBROLIZUMAB COMPARED TO CHEMOTHERAPY AS A TREATMENT FOR PATIENTS WITH PREVIOUSLY TREATED ADVANCED MELANOMA IN CHINA

    Oct 1, 2019, 00:00

  • PIN13 BUDGET IMPACT ANALISIS ( BIA) OF THE IMPLEMENTATION OF HIGH-RISK HPV GENOTYPING IN PATIENTS OF THE SOCIAL SECURITY OF ECUADOR (IESS) FOR PREVENTION OF CERVICAL CANCER

    Oct 1, 2019, 00:00

  • PMS11 EPIDEMIOLOGY, USE OF RESOURCES AND COST OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN ARGENTINA: AN EXTENSIVE REVIEW WITH EXPERT ELICITATION

    Oct 1, 2019, 00:00

  • PDB8 IMPACTO ECONOMICO DE LA DIABETES MELLITUS TIPO II EN EL PERU EN EL ANHO 2017

    Oct 1, 2019, 00:00

  • PNS30 CHANGES IN THE OWNERSHIP STRUCTURE OF HUNGARIAN HEALTH CARE PROVIDERS

    Oct 1, 2019, 00:00

  • PND17 THE BURDEN OF MIGRAINE IN LATIN AMERICA

    Oct 1, 2019, 00:00

  • PNS44 COORDENAÇÃO DE CUIDADOS DE SAÚDE ATRAVÉS DE UM APLICATIVO MÓVEL COMO FATOR DE MELHOR RESULTADO CLÍNICO E REDUÇÃO DE CUSTOS

    Oct 1, 2019, 00:00

  • PIN16 ESTIMATED ANNUAL IMPACT OF PNEUMOCOCCAL CONJUGATE VACCINE (PCV) IMMUNIZATION PROGRAM IN COLOMBIA (2011-2018)

    Oct 1, 2019, 00:00

  • PND19 RETROSPECTIVE ANALYSIS OF MULTIPLE SCLEROSIS TREATMENT PROFILE AND PATTERNS IN THE BRAZILIAN PUBLIC HEALTH SYSTEM

    Oct 1, 2019, 00:00

  • PCN67 ANALYSIS OF TREATMENT PATTERNS FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN SUPPLEMENTARY HEALTHCARE SYSTEM IN DIFFERENT GEOGRAPHIC REGIONS OF BRAZIL

    Oct 1, 2019, 00:00

  • PCN1 EFECTIVIDAD Y SEGURIDAD DEL ESQUEMA DABRAFENIB-TRAMETINIB EN EL TRATAMIENTO DEL MELANOMA AVANZADO/METASTÁSICO IRRESECABLE CON MUTACIÓN BRAF V600: REVISIÓN SISTEMÁTICA DE LA LITERATURA Y METANÁLISIS EN RED

    Oct 1, 2019, 00:00

  • Financial Disclosure Information

    Oct 1, 2019, 00:00

  • PRS9 ESTIMATIVA DO CUSTO DA ASMA EM UM PLANO DE SAUDE NO BRASIL - ESTUDO DE MUNDO REAL

    Oct 1, 2019, 00:00

  • CV3 COST-EFFECTIVENESS OF A COMPREHENSIVE INTERVENTION FOR HYPERTENSION CONTROL IN LOW-INCOME SETTINGS IN ARGENTINA: A MARKOV MODEL

    Oct 1, 2019, 00:00

  • PCV4 ANNUAL HEALTH INSURANCE TREATMENT COST OF HYPERTENSIVE RENAL DISEASE IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Oct 1, 2019, 00:00

  • HT4 EXPERIENCIAS INTERNACIONALES ACERCA DE LOS CRITERIOS DE DECISIÓN USADOS EN LA PRIORIZACIÓN DE LAS TECNOLOGÍAS DE SALUD

    Oct 1, 2019, 00:00

  • PUK5 POTENTIALLY INAPPROPRIATE PRESCRIPTIONS OF ANTICHOLINERGIC DRUGS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA

    Oct 1, 2019, 00:00

  • PUK3 COST CONSEQUENCE ANALYSIS OF A REMOTE PATIENT MONITORING PROGRAM TO IMPROVE CLINICAL PRACTICE OF AUTOMATED PERITONEAL DYALISIS IN BRAZIL

    Oct 1, 2019, 00:00

  • CV4 EVALUACION DE LOS MOTIVOS DE LA OMISION DE RETIROS DE MEDICAMENTOS PENDIENTES EN LA OFICINA DE FARMACIA. POSIBLES SOLUCIONES

    Oct 1, 2019, 00:00

  • PCN58 CANCER PATIENTS PREFER REPORTING SYMPTOMS IN DAILY ELECTRONIC DIARIES AT HOME

    Oct 1, 2019, 00:00

  • CM2 REMOTE MONITORING AFTER THE IMPLANTATION OF A CARDIOVERTER-DEFIBRILLATOR: A SYSTEMATIC REVIEW AND META-ANALYSIS

    Oct 1, 2019, 00:00

  • PCN60 EVALUATION OF EMOTIONAL, SOCIAL AND ACCESS NEEDS OF PATIENTS DIAGNOSED WITH CHRONIC MYELOID LEUKEMIA IN COLOMBIA.

    Oct 1, 2019, 00:00

  • PMS3 PSYCHOLOGY CONSULTATION FOR PATIENTS WITH RHEUMATOID ARTHRITIS - A LOW-COST INTERVENTION WITH GREAT BENEFITS

    Oct 1, 2019, 00:00

  • PMH9 IMPACTO DE FACTORES SOCIOLOGICOS EN LA CALIDAD DE VIDA DE ADULTOS MAYORES INSTITUCIONALIZADOS CON DEPRESION: REVISION SISTEMATICA

    Oct 1, 2019, 00:00

  • PNS49 EVOLUTION AND RESULTS OF HEALTHCARE PERFORMANCE INDICATORS IN BRAZILIAN SELF-FUNDED HEALTH PLANS

    Oct 1, 2019, 00:00

  • PGI9 PRIOR DIAGNOSIS OF GASTROINTESTINAL DISORDER DOES NOT INCREASE KNOWLEDGE OF GASTROINTESTINAL TERMINOLOGY OR ACCURACY OF SYMPTOM RATING

    Oct 1, 2019, 00:00

  • TP4 REAL-WORLD PATIENT CHARACTERISTICS AND OUTCOMES OF RESECTED STAGE III MELANOMA PATIENTS IN ARGENTINA AND BRAZIL

    Oct 1, 2019, 00:00

  • PMS9 EVALUACIÓN DE LA INCLUSIÓN DE DENOSUMAB EN EL PLAN DE BENEFICIOS DE SALUD EN COLOMBIA PARA EL TRATAMIENTO DE LA OSTEOPOROSIS: ANÁLISIS DE IMPACTO PRESUPUESTAL

    Oct 1, 2019, 00:00

  • PRO8 PROFILAXIS EN HEMOFILIA A CON INHIBIDORES EN COLOMBIA, ¿ES POSIBLE CONTAR CON TRATAMIENTOS QUE GENEREN AHORROS AL SISTEMA DE SALUD?

    Oct 1, 2019, 00:00

  • PNS21 EFECTIVIDAD DE INTERVENCIONES DE EDUCACION SEXUAL EN ADOLESCENTES: REVISION DE REVISIONES

    Oct 1, 2019, 00:00

  • CN4 ANÁLISIS DE COSTO-UTILIDAD E IMPACTO PRESUPUESTARIO DE LA ENZALUTAMIDA PARA EL TRATAMIENTO DEL CÁNCER DE PRÓSTATA RESISTENTE A LA CASTRACIÓN NO METASTÁSICO (CPRCNM) EN ARGENTINA

    Oct 1, 2019, 00:00

  • PMH3 ESKETAMINE SELF-PAY MODEL FOR TREATMENT RESISTANT DEPRESSION IN MEXICO

    Oct 1, 2019, 00:00

  • PSY4 BURDEN OF DISEASE FOR RHEUMATOID ARTHRITIS IN COLOMBIA AND BRAZIL

    Oct 1, 2019, 00:00

  • PDG5 BUDGET IMPACT ANALYSIS OF CLADRIBINE IN HIGH DISEASE ACTIVITY RELAPSE REMITTING MULTIPLE SCLEROSIS IN ARGENTINA

    Oct 1, 2019, 00:00

  • EP2 PUBLIC HEALTH AND ECONOMIC IMPACT OF A QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINATION PROGRAM FOR FEMALES AGED 9 YEARS IN EL SALVADOR

    Oct 1, 2019, 00:00

  • PNS4 TRENDS FOR INTRODUCTION OF APPROVED DRUGS IN NETWORK META-ANALYSIS

    Oct 1, 2019, 00:00

  • PCN41 IMPACT OF DISEASE RELATED GROUP IN BREAST CANCER TREATMENT IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM

    Oct 1, 2019, 00:00

  • CN3 SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS OF COLORECTAL CANCER SCREENING STRATEGIES FOR THE EARLY DETECTION OF COLORECTAL CANCER IN THE GENERAL POPULATION

    Oct 1, 2019, 00:00

  • PMS13 A ROUTE FOR THE CORRECT DIAGNOSIS OF RHEUMATOID ARTHRITIS - AN OPPORTUNITY TO AVOID MISDIAGNOSIS AND COSTS ASSOCIATED

    Oct 1, 2019, 00:00

  • PCN65 ANÃLISIS COMPARATIVO DE CUSTOS DE PACIENTES DE CÃNCER POR REGIÃO GEOGRÃFICA

    Oct 1, 2019, 00:00

  • PDB4 COST-EFFECTIVENESS ANALYSIS OF SWITCHING FROM ALOGLIPTIN TO VILDAGLIPTIN IN THE TREATMENT OF TYPE 2 DIABETES

    Oct 1, 2019, 00:00

  • PNS6 VALUE-ASSESSMENT FRAMEWORKS: WE CANNOT ESCAPE THE ETHICAL DILEMMAS POSED BY THEIR USE

    Oct 1, 2019, 00:00

  • PIN28 COSTS OF PERTUSSIS IN BRAZIL: A NINE-YEAR EVALUATION

    Oct 1, 2019, 00:00

  • PNS9 BUDGET IMPACT OF NEW RECOMMENDATION FOR ATROPINIZATION IN BRAZILIAN GUIDELINES FOR ANTICOLINESTARASIS INTOXICATION

    Oct 1, 2019, 00:00

  • PIN3 COSTS AND CONSEQUENCES OF CEFTAROLINE FOSAMIL FOR THE TREATMENT OF COMPLICATED SKIN AND SOFT TISSUE INFECTIONS (CSSTI) IN BRAZILIAN PRIVATE HEALTHCARE SYSTEM

    Oct 1, 2019, 00:00

  • PND8 ANALISIS DE MINIMIZACION DE COSTOS DE TOXINA ONABOTULINICA A 100 U EN PACIENTES CON BLEFAROESPASMO Y TORTICOLIS ESPASMODICA

    Oct 1, 2019, 00:00

  • PCV6 ECONOMIC EVALUATION OF GLOBAL LONGITUDINAL STRAIN IN THE EARLY DETECTION OF CARDIOTOXICITY IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

    Oct 1, 2019, 00:00

  • PCN7 COSTOS DE LOS EVENTOS ADVERSOS ASOCIADOS CON EL TRATAMIENTO DEL MIELOMA MULTIPLE REFRACTARIO RECIDIVANTE (MMRR) EN ARGENTINA

    Oct 1, 2019, 00:00

  • PDG11 IMPLEMENTATION OF INDICATORS IN THE PROCESS OF ACQUISITION OF MEDICINES IN THE HOSPITAL UNITS OF THE STATE SECRETARIAT OF HEALTH OF SANTA CATARINA: THE USE OF THE ECONOMIC RATIO INDEX

    Oct 1, 2019, 00:00

  • PMD6 CENTRIFUGAL VERSUS MEMBRANE THERAPEUTIC PLASMA EXCHANGE: A CHILEAN, MULTI-CENTER, COST-COMPARISON STUDY

    Oct 1, 2019, 00:00

  • PNS43 ESTIMACIÓN DE UN COSTO DE REFERENCIA PARA EVENTOS HOSPITALARIOS MEDIANTE NORMALIZACIÓN DE DATOS

    Oct 1, 2019, 00:00

  • PIH9 IMPACTO ECONOMICO DE ANEMIA Y SU TENDENCIA AL 2030 EN EL SISTEMA DE SALUD PUBLICO DEL PERU

    Oct 1, 2019, 00:00

  • PCV9 IMPACTO CLINICO Y ECONOMICO DE LAS ENFERMEDADES CARDIOVASCULARES (ECV) EN LA POBLACION ADULTA DENTRO DEL SISTEMA DE SALUD DE MEXICO.

    Oct 1, 2019, 00:00

  • PCN22 ESTUDIO DE COSTO EFECTIVIDAD DE RIBOCICLIB/LETROZOL PARA EL TRATAMIENTO DEL CANCER DE MAMA METASTASICO CON RECEPTORES DE HORMONA POSITIVO Y HER-2 NEGATIVO DESDE LA PERSPECTIVA DEL SISTEMA DE SALUD PUBLICO CHILENO

    Oct 1, 2019, 00:00

  • PBI1 THE VALUE OF ONASEMNOGENE ABEPARVOVEC (AVXS-101) AS A COST-EFFECTIVE GENE REPLACEMENT THERAPY FOR SPINAL MUSCULAR ATROPHY TYPE 1 IN IMPROVING SURVIVAL, HEALTHCARE RESOURCE UTILIZATION, AND MOTOR FUNCTION

    Oct 1, 2019, 00:00

  • PCN66 IDENTIFICATION OF PATIENTS UNDERGOING TREATMENT OF LUNG CANCER IN THE BRAZILIAN NATIONAL HEALTH SYSTEM (SUS)

    Oct 1, 2019, 00:00

  • PNS29 CHANGING OF HEALTH CARE TOURISM AND ITS RECOVERING ROLE FOR ECONOMY

    Oct 1, 2019, 00:00

  • PRO5 ASSESSMENT OF COST-EFFECTIVENESS RESULTS FROM ICER ADVANCED THERAPIES MEDICINAL PRODUCTS REVIEWS

    Oct 1, 2019, 00:00

  • PND6 THE DIRECT COSTS OF MULTIPLE SCLEROSIS IN A GROUP OF COLOMBIAN PATIENTS

    Oct 1, 2019, 00:00

  • PIT4 SILICONE TAPES FOR PATIENTS WITH FRAGILE SKIN: A SYSTEMATIC REVIEW

    Oct 1, 2019, 00:00

  • PCN17 COSTO-EFECTIVIDAD DE AFATINIB COMO PRIMERA LÍNEA EN EL TRATAMIENTO DEL CÁNCER DE PULMÓN DE CÉLULAS NO PEQUEÑAS AVANZADO CON MUTACIÓN POSITIVA DEL RECEPTOR DEL FACTOR DE CRECIMIENTO EPIDÉRMICO EN COLOMBIA

    Oct 1, 2019, 00:00

  • PUK6 AN EVALUATION OF THE BRAZILIAN POLICY FOR THE MANAGEMENT OF CHRONIC KIDNEY DISEASE UNDER THE PERSPECTIVE OF THE PUBLIC HEALTH CARE SYSTEM: WAS IT EFFECTIVE?

    Oct 1, 2019, 00:00

  • PBI3 ANÁLISIS DEL COSTO POR RESPONDEDOR DE SECUKINUMAB VS INFLIXIMAB Y ETANERCEPT PARA EL TRATAMIENTO DE LA ARTRITIS PSORIÁSICA DESDE UNA PERSPECTIVA ECUATORIANA

    Oct 1, 2019, 00:00

  • PIN21 PROFILING PURCHASE VOLUMES AND EXPENDITURES WITH DIRECT-ACTING ANTIRETROVIRALS FOR HEPATITIS C BY THE BRAZILIAN MINISTRY OF HEALTH, 2015-2018

    Oct 1, 2019, 00:00

  • PNS46 ATENCION VIRTUAL EN SALUD: DE LA ESTRATEGIA A LA TACTICA

    Oct 1, 2019, 00:00

  • PIN25 CALIDAD DE REVISIONES SISTEMATICAS CON EVALUACIONES DE COSTO-EFECTIVIDAD DE LA VACUNA CONTRA ROTAVIRUS DE PAISES LATINOAMERICANOS

    Oct 1, 2019, 00:00

  • PMD13 BUNDLE AND RISK SHARING FOR BARIATRIC SURGERY UNDER THE VALUE-BASED CARE (VBC) MODEL: MODEL EFFECTIVENESS AND SUSTAINABILITY AT HOSPITAL ALEMAO OSWALDO CRUZ (HAOC) BASED IN CLINICAL AND ECONOMICAL RESULTS

    Oct 1, 2019, 00:00
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9 (current)
  • 10
  • »